Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2231232 | 0.84 | DGKA (0.35) | DGKACYP1A2ALDH1A1ALOX15TDP1 | |
| SCHEMBL15617982 | 0.81 | TSHR (0.38) | TSHR | |
| SCHEMBL15268078 | 0.77 | — | — | |
| SCHEMBL8657397 | 0.76 | CYP1A2 (0.52) | DGKACYP1A2ALDH1A1ALOX15TDP1 | |
| SCHEMBL9355489 | 0.76 | CYP1A2 (0.52) | DGKACYP1A2ALDH1A1ALOX15TDP1 | |
| SCHEMBL9351131 | 0.76 | CYP1A2 (0.52) | DGKACYP1A2ALDH1A1ALOX15TDP1 | |
| SCHEMBL9355503 | 0.76 | CYP1A2 (0.52) | DGKACYP1A2ALDH1A1ALOX15TDP1 | |
| SCHEMBL9355058 | 0.76 | CYP1A2 (0.52) | DGKACYP1A2ALDH1A1ALOX15TDP1 | |
| SCHEMBL9355150 | 0.76 | CYP1A2 (0.52) | DGKACYP1A2ALDH1A1ALOX15TDP1 | |
| SCHEMBL3052283 | 0.76 | CYP1A2 (0.52) | DGKACYP1A2ALDH1A1ALOX15TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170173107-A1 | Compstatin Analogs With Improved Potency and Pharmacokinetic Properties | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-06-22 | — | — | US | disclosed |
| WO-2015142701-A1 | COMPSTATIN ANALOGS WITH IMPROVED POTENCY AND PHARMACOKINETIC PROPERTIES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-09-24 | — | — | WO | disclosed |
| US-20150080427-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | AUSPEX PHARMACEUTICALS, INC. | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080427-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | SLC18A2, SLC6A2, SLC18A1 | DGKA 3573/4885CYP1A2 280/4885ALDH1A1 824/4885 |
| US-20170173107-A1 | Compstatin Analogs With Improved Potency and Pharmacokinetic Properties | CFB, C3AR1, C9 | DGKA 4764/4885CYP1A2 4721/4885ALDH1A1 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.